Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-Line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkins Lymphoma: A Randomized, Controlled, Phase III Comparative Trial.
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Pixantrone (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms EXTEND
- Sponsors CTI BioPharma
- 17 Jun 2013 Results from post-hoc sub-set analyses presented at the 18th Congress of the European Hematology Association, according to a Cell Therapeutics media release.
- 29 May 2012 Results published in Lancet Oncology.
- 06 Dec 2010 Results will be presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History